Meeting
2023 ASCO Annual Meeting
Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi‑center, randomized, open‑label trial.
Authors
Yuanming Shen
Women's Hospital School of Medicine Zhejiang University, Hangzhou, Zhejiang, China
Yuanming Shen , Beihua Kong , Bairong Xia , Fei Wang , Rutie Yin , Qingshui Li , Ying Yue , Shan Kang , Liping He , Ke Wang , Yuanguang Meng , Shixuan Wang , Pengpeng Qu , Xianghua Huang , Ruixia Guo , Ping Yan , Mei Pan , Ge Lou , Wenjun Cheng , Xing Xie
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT03794778
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5556)
DOI
10.1200/JCO.2023.41.16_suppl.5556
Abstract #
5556
Poster Bd #
251
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus either Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.
First Author: Thomas J. Herzog
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of adding nivolumab to first-line chemotherapy in patients with advanced gastric cancer.
First Author: Mai Utsumi
Poster
2013 ASCO Annual Meeting
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research Institute.
First Author: Dana Shelton Thompson
Poster
2011 ASCO Annual Meeting
Final overall survival results of NEJ002, a phase 3 trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.
First Author: A. Inoue